This is the authors' abstract. We don't add key points for this paper.
After 7 years of treatment, children with GHD receiving somapacitan experienced consistent increases in height SDS and reduced treatment burden. No new safety concerns were identified.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sävendahl et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: